Neogen (NEOG) Competitors $14.60 -0.04 (-0.27%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends NEOG vs. CLDX, VIVO, NTLA, MYGN, MMSI, HAE, ICUI, XRAY, QDEL, and STAAShould you be buying Neogen stock or one of its competitors? The main competitors of Neogen include Celldex Therapeutics (CLDX), Meridian Bioscience (VIVO), Intellia Therapeutics (NTLA), Myriad Genetics (MYGN), Merit Medical Systems (MMSI), Haemonetics (HAE), ICU Medical (ICUI), DENTSPLY SIRONA (XRAY), QuidelOrtho (QDEL), and STAAR Surgical (STAA). These companies are all part of the "medical" sector. Neogen vs. Celldex Therapeutics Meridian Bioscience Intellia Therapeutics Myriad Genetics Merit Medical Systems Haemonetics ICU Medical DENTSPLY SIRONA QuidelOrtho STAAR Surgical Celldex Therapeutics (NASDAQ:CLDX) and Neogen (NASDAQ:NEOG) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, community ranking, valuation, profitability, dividends, risk, media sentiment and institutional ownership. Is CLDX or NEOG more profitable? Neogen has a net margin of -2.58% compared to Celldex Therapeutics' net margin of -1,544.32%. Neogen's return on equity of 2.80% beat Celldex Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Celldex Therapeutics-1,544.32% -19.75% -18.86% Neogen -2.58%2.80%1.93% Does the media prefer CLDX or NEOG? In the previous week, Celldex Therapeutics had 17 more articles in the media than Neogen. MarketBeat recorded 20 mentions for Celldex Therapeutics and 3 mentions for Neogen. Neogen's average media sentiment score of 0.42 beat Celldex Therapeutics' score of 0.39 indicating that Neogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celldex Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Neogen 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, CLDX or NEOG? Celldex Therapeutics has a beta of 1.6, indicating that its share price is 60% more volatile than the S&P 500. Comparatively, Neogen has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500. Which has stronger earnings & valuation, CLDX or NEOG? Neogen has higher revenue and earnings than Celldex Therapeutics. Neogen is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCelldex Therapeutics$9.98M156.62-$141.43M-$2.57-9.16Neogen$912.20M3.47-$9.42M-$0.11-132.73 Does the MarketBeat Community believe in CLDX or NEOG? Celldex Therapeutics received 286 more outperform votes than Neogen when rated by MarketBeat users. Likewise, 75.12% of users gave Celldex Therapeutics an outperform vote while only 56.60% of users gave Neogen an outperform vote. CompanyUnderperformOutperformCelldex TherapeuticsOutperform Votes61675.12% Underperform Votes20424.88% NeogenOutperform Votes33056.60% Underperform Votes25343.40% Do insiders and institutionals have more ownership in CLDX or NEOG? 96.7% of Neogen shares are held by institutional investors. 3.8% of Celldex Therapeutics shares are held by company insiders. Comparatively, 1.1% of Neogen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Do analysts recommend CLDX or NEOG? Celldex Therapeutics currently has a consensus price target of $62.25, indicating a potential upside of 164.33%. Neogen has a consensus price target of $17.50, indicating a potential upside of 19.86%. Given Celldex Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Celldex Therapeutics is more favorable than Neogen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Celldex Therapeutics 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.89Neogen 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryCelldex Therapeutics beats Neogen on 11 of the 19 factors compared between the two stocks. Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Get Neogen News Delivered to You Automatically Sign up to receive the latest news and ratings for NEOG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NEOG vs. The Competition Export to ExcelMetricNeogenDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.16B$2.51B$5.06B$8.67BDividend YieldN/A0.74%5.06%4.06%P/E Ratio-132.734.8598.4317.07Price / Sales3.4727.511,206.2371.09Price / Cash14.8115.1340.6936.36Price / Book1.013.036.325.87Net Income-$9.42M$29.98M$119.47M$225.66M7 Day Performance-10.04%-11.24%-5.11%-1.34%1 Month Performance-0.07%-13.18%-3.21%1.00%1 Year Performance-8.46%-19.98%32.41%25.27% Neogen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NEOGNeogen2.224 of 5 stars$14.60-0.3%$17.50+19.9%-8.5%$3.16B$912.20M-132.732,640CLDXCelldex Therapeutics2.7984 of 5 stars$23.55-8.5%N/A-15.3%$1.56B$9.98M-9.16160Insider BuyingVIVOMeridian Bioscience1.0694 of 5 stars$33.97flatN/AN/A$1.50B$333.02M35.02702NTLAIntellia Therapeutics4.5291 of 5 stars$13.97-7.6%N/A-46.3%$1.42B$36.28M-2.57600Gap UpHigh Trading VolumeMYGNMyriad Genetics4.2988 of 5 stars$15.25-2.7%N/A-11.4%$1.39B$753.20M-11.732,700Analyst UpgradeNews CoverageMMSIMerit Medical Systems4.3915 of 5 stars$101.83+0.6%N/A+42.2%$5.93B$1.26B49.926,950Short Interest ↑Positive NewsHAEHaemonetics4.784 of 5 stars$89.22-1.7%N/A+0.0%$4.48B$1.36B37.023,657Analyst ForecastNews CoverageICUIICU Medical4.1571 of 5 stars$167.86-2.4%N/A+92.7%$4.11B$2.26B-36.7314,000Analyst DowngradeShort Interest ↓News CoverageXRAYDENTSPLY SIRONA4.9012 of 5 stars$18.28+2.3%N/A-38.2%$3.63B$3.97B-8.8315,000QDELQuidelOrtho4.437 of 5 stars$36.18-7.1%N/A-44.8%$2.43B$2.82B-1.307,100Options VolumeSTAASTAAR Surgical4.8603 of 5 stars$26.66-2.3%N/A-24.4%$1.31B$341.22M60.591,115Short Interest ↓ Related Companies and Tools Related Companies CLDX Competitors VIVO Competitors NTLA Competitors MYGN Competitors MMSI Competitors HAE Competitors ICUI Competitors XRAY Competitors QDEL Competitors STAA Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NEOG) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredNvidia’s world of pain awaitsThe Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neogen Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neogen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
